Kaposi Sarcoma Market is segmented By Type (Epidemic (AIDS-associated) Kaposi sarcoma, Classic (Mediterranean) Kaposi sarcoma, Endemic (African) Kaposi sarcoma, Iatrogenic (transplant-related) Kaposi sarcoma), By Diagnostics (Biopsy, Bronchoscopy, Gastrointestinal endoscopy, Others), By Treatment (Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Chemotherapy, Immunotherapy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Kaposi Sarcoma Market is expected to grow at a CAGR of 5.5% during the forecast period 2024-2031.
Kaposi sarcoma refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. Cancer usually appears as tumors on mucosal surfaces or the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal Kaposi sarcoma cells cause brown, purple, or red blotches on the skin, called lesions.
Kaposi Sarcoma Market Scope
|
Metrics |
Details |
|
Market CAGR |
5.5% |
|
Segments Covered |
By Type, By Diagnostics, By Treatment, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For more insights - Download the Sample
Kaposi Sarcoma Market Dynamics
The global Kaposi sarcoma market growth is driven by the rising number of regional vendors commanding prominent shares in their respective regional territories. Owing to the looming patent expiries of several blockbuster drugs, the market is expected to witness the entry of several new companies producing generics. The situation also presents immense growth opportunities for leading companies with new drug formulations in the next few years.
The growing prevalence of Kaposi Sarcoma is expected to drive growth in the forecast period
The growing prevalence of Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible to Kaposi sarcoma are the major factors attributing to the growth of the Kaposi sarcoma market.
According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017, where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, a promising number of pipeline studies and a growing incidence of HIV-associated Kaposi sarcoma are also major factors driving the Kaposi sarcoma market.
The introduction of new drugs for Kaposi sarcoma is projected, expected to drive the market growth
The technological advancements in the healthcare sector and the introduction of new drugs for Kaposi sarcoma are projected to enhance the growth of the Kaposi sarcoma market in the forecast period. However, the increased incidence rate of cardiac diseases, kidney diseases, liver diseases, and type 2 diabetes worldwide will drive the global Kaposi sarcoma market.
Shortage in the supply of drugs due to a wide demand-supply gap is likely to hinder the market growth
However, the shortage in the supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment, and diagnosis of Kaposi sarcoma will hamper the growth of the market in the forecast period.
COVID-19 Impact on Kaposi Sarcoma Market Growth
The COVID-19 pandemic has impacted every aspect of cancer care and research from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows. The report, by researchers at Dana-Farber Cancer Institute and other institutions, suggests that while COVID-19 has complicated the treatment of cancer patients, it has also spurred creative solutions to challenges in clinical care, and research into the new disease is benefiting from insights gained over years of cancer research. This factor will hinder the growth of the market in the forecast period.
Kaposi Sarcoma Market Segmentation
The biopsy, segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The growing prevalence of cancer worldwide and the presence of untapped opportunities in emerging economies, along with improving healthcare infrastructure are driving the market growth. Surging demand for effective diagnostic procedures for cancer is also expected to work in favor of the market.
Furthermore, spiraling demand for less invasive surgeries and disposable biopsies is anticipated to drive the market. According to statistics published by WHO, cancer has become one of the leading causes of death worldwide. The global incidence of cancer in 2012 was 14.1 million and it is awaited to rise by 70.0% over the next two decades.
The most common types of cancers that prove to be fatal for patients are colorectal cancer, breast cancer, lung cancer, liver cancer, and stomach cancer. The number of cases of cancer is likely to reach 23.6 million by 2030. The rising incidence of cancer is encouraging the development of more effective, safe, and advanced biopsy procedures that will drive market growth. Therefore, with growing cancer cases worldwide, the number of biopsies is to increase in the market in the forecast period.
Highly Active Antiretroviral Therapy (HAART), is expected to dominate the Kaposi Sarcoma market during the forecast period
Kaposi sarcoma is common cancer associated with HIV infection and it is considered an AIDS-defining condition by the US Centers for Disease Control Guidelines. Numerous advancements in the treatment of AIDS-related Kaposi sarcoma have been attained over the last few years, but the introduction of highly active antiretroviral therapy (HAART) has declined the incidences of AIDS-defining illnesses, including Kaposi sarcoma.
For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV/AIDS is generally used before any other therapies for treating the tumor and reducing the symptoms. HAART might be given as individual therapy or in combination with chemotherapy depending on the spread of the disease and the patient’s symptoms. Seldom, HAART might worsen the condition of the Kaposi sarcoma and the pre-existing infections which leads to a condition called immune reconstitution inflammatory syndrome (IRIS).
Kaposi Sarcoma Market Geographical Share
North America region holds the largest market share global Kaposi sarcoma market
North America region is dominating the global Kaposi Sarcoma market and accounted for the largest market share in 2020. Major factors contributing to this position of market in the region are the increasing number of product approvals, the presence of a large number of market players, a high number of R&D initiatives undergoing treatment, and the diagnosis of Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also driving market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma. This factor is driving the growth of the market in the region.
Moreover, the region is expected to lead to heightened demand for Kaposi sarcoma drugs owing to the high rate of incidence of the disease. The high rate of prevalence of HIV/AIDS and thus the increased prevalence of AIDS-induced Kaposi sarcoma in the region is projected to drive market growth over the forecast period.
Kaposi Sarcoma Companies and Competitive Landscape
The Kaposi Sarcoma market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co., Navidea Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Kaposi sarcoma market globally.
Kaposi Sarcoma Market Key Companies to Watch
Pfizer Inc.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars, and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company’s portfolio comprised of includes internal medicine, vaccines, oncology, inflammation and immunology and rare diseases, and others.
